Health-Related Quality of Life in Male Patients under Treatment for Substance Use Disorders with and without Major Depressive Disorder: Influence in Clinical Course at One-Year Follow-Up.

dual depression dual disorders health-related quality of life major depressive disorder relapses substance use disorder

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
26 Sep 2020
Historique:
received: 29 07 2020
revised: 17 09 2020
accepted: 23 09 2020
entrez: 30 9 2020
pubmed: 1 10 2020
medline: 1 10 2020
Statut: epublish

Résumé

Health-related quality of life (HRQoL) assessment has interest as an indicator of degree of affectation and prognosis in mental disorders. HRQoL is impaired in both Substance Use Disorder (SUD) and Major Depressive Disorder (MDD), two conditions highly prevalent, although less studied when both are coexisting (SUD + MDD). Hence, we decided to explore HRQoL with the SF-36 survey in a sample of 123 SUD and 114 SUD + MDD patients (51 symptomatic and 63 asymptomatic of depressive symptoms) under treatment. We performed analyses to examine HRQoL among groups, and its predictive value at 3-, 6- and 12-month follow-ups through regression models. Patients with SUD + MDD had worse HRQoL than SUD patients and population norms. For Mental Health, Vitality, and General Health dimensions, lower scores were observed for SUD + MDD regardless the presence/absence of depressive symptoms. For Physical Functioning and Health Change, depressive symptomatology and not the comorbidity of SUD + MDD diagnoses explained HRQoL limitations. At 3-, 6- and 12-month follow-ups we observed two predictors of relapses, General Health for asymptomatic SUD + MDD, and Physical Functioning for SUD. Improving HRQoL in SUD + MDD may be targeted during patient's treatment; future studies should explore the influence of HRQoL on patient's prognosis taking into account the presence/absence of depressive symptomatology.

Identifiants

pubmed: 32993107
pii: jcm9103110
doi: 10.3390/jcm9103110
pmc: PMC7601390
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Spanish Ministry of Economy, Industry and Competitiveness
ID : PSI2015-65026-MINECO/FEDER/UE
Organisme : Generalitat de Catalunya
ID : 2017SGR-748
Organisme : Spanish Ministry of Economy and Business
ID : PSI2017-90806-REDT

Références

Psychol Med. 2012 Apr;42(4):695-703
pubmed: 21867593
Qual Life Res. 2005 Jun;14(5):1263-74
pubmed: 16047502
Asia Pac Psychiatry. 2013 Dec;5(4):276-83
pubmed: 23857826
Psychiatry Res. 2015 Jan 30;225(1-2):115-121
pubmed: 25467698
Am J Addict. 2016 Jan;25(1):49-55
pubmed: 26692463
Phys Ther. 2010 Dec;90(12):1711-5
pubmed: 21123213
J Affect Disord. 2010 Jan;120(1-3):126-32
pubmed: 19446342
Addiction. 2012 Apr;107(4):709-18
pubmed: 21981638
Med Clin (Barc). 2002 Apr 13;118(13):493-9
pubmed: 11975886
Addiction. 2011 May;106(5):906-14
pubmed: 21382111
Health Qual Life Outcomes. 2017 Oct 23;15(1):209
pubmed: 29061151
Qual Life Res. 2016 Nov;25(11):2941-2956
pubmed: 27245776
Nord J Psychiatry. 2017 Apr;71(3):197-204
pubmed: 27834103
Am J Addict. 2015 Jun;24(4):308-14
pubmed: 25808055
Psychiatry Res. 2019 Jun;276:283-289
pubmed: 31128488
Front Psychiatry. 2019 Jan 11;9:764
pubmed: 30687142
J Affect Disord. 2014 Sep;166:173-8
pubmed: 25012428
Addiction. 2013 Jan;108(1):115-23
pubmed: 22775406
Med Clin (Barc). 1998 Oct 10;111(11):410-6
pubmed: 9834913
Scand J Caring Sci. 2011 Jun;25(2):262-8
pubmed: 20731793
Turk Psikiyatri Derg. 2009 Fall;20(3):205-12
pubmed: 19757220
J Subst Abuse Treat. 2014 Oct;47(4):293-8
pubmed: 25012552
Psychiatry Res. 2017 Jan;247:113-119
pubmed: 27888680
Qual Life Res. 2019 Nov;28(11):2919-2928
pubmed: 31227958
Nord J Psychiatry. 2002;56(4):261-4
pubmed: 12470316
Issues Ment Health Nurs. 2017 Jan;38(1):80-91
pubmed: 27901625
Alcohol Alcohol. 2012 Nov-Dec;47(6):702-10
pubmed: 22986010
J Clin Med. 2019 Nov 14;8(11):
pubmed: 31739487
BMC Med. 2015 Jan 30;13:20
pubmed: 25637245
Am J Psychiatry. 2002 Sep;159(9):1600-2
pubmed: 12202286
Addict Behav. 2016 Nov;62:114-21
pubmed: 27344118
Curr Opin Psychiatry. 2008 Jan;21(1):14-8
pubmed: 18281835
Actas Esp Psiquiatr. 1999 Mar-Apr;27(2):71-80
pubmed: 10380180
Health Qual Life Outcomes. 2012 Sep 05;10:106
pubmed: 22950596
Health Qual Life Outcomes. 2019 Nov 8;17(1):169
pubmed: 31703701
Addict Sci Clin Pract. 2011 Jul;6(1):44-55
pubmed: 22003421
Subst Use Misuse. 2008;43(5):612-32
pubmed: 18393080
Med Care. 1992 Jun;30(6):473-83
pubmed: 1593914
PLoS One. 2019 Jul 11;14(7):e0219455
pubmed: 31295291
J Ment Health. 2017 Apr;26(2):119-126
pubmed: 27128492
J Dual Diagn. 2015;11(1):33-41
pubmed: 25491440
Drug Alcohol Depend. 2011 Jan 15;113(2-3):147-56
pubmed: 20801586
Drug Alcohol Depend. 2015 Sep 1;154:1-13
pubmed: 26072219
Can J Surg. 2009 Aug;52(4):328-336
pubmed: 19680521

Auteurs

Julia E Marquez-Arrico (JE)

Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.

José Francisco Navarro (JF)

Department of Psychobiology, School of Psychology, University of Málaga, Campus de Teatinos s/n, 29071 Málaga, Spain.

Ana Adan (A)

Department of Clinical Psychology and Psychobiology, School of Psychology, University of Barcelona, Passeig de la Vall d'Hebrón 171, 08035 Barcelona, Spain.
Institute of Neurosciences, University of Barcelona, 08035 Barcelona, Spain.

Classifications MeSH